Navigation Links
Strides Arcolab makes strategic investment in Oncobiologics, Inc., USA

BANGALORE, India and CRANBURY, N.J., July 16, 2014 /PRNewswire/ -- Strides Arcolab and Oncobiologics, Inc., today announced that Strides has made a series of strategic investments in Oncobiologics, Inc., a privately held New Jersey biopharmaceutical firm developing a pipeline of biosimilars and next generation biotherapeutics.

The investment is part of Strides' strategy to fund promising biopharma companies with high quality scientific management and proprietary approaches to developments that confer significant time and cost advantages.

Financial terms were not disclosed.

"The investments by Strides Arcolab represent important milestones for Oncobiologics. Strides Arcolab is a long-term strategic partner that provides both financial strength and a proven track-record of successful business ventures. We look forward to their support and guidance as we continue to execute Oncobiologics' business and technical plans," said Oncobiologics Founder & CEO, Pankaj Mohan, Ph.D.  

Commenting on the development, Arun Kumar, Founder and Group CEO of Strides Arcolab said, "Strides Arcolab is proud to announce this strategic partnership with Oncobiologics. After significant due diligence, it is evident that their success to-date in meeting technical milestones is an indicator of the solid team and business model they have constructed. We look forward to sharing in Oncobiologics' future successes."

About Strides Arcolab Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical Company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products. Strides has made significant investments in its own Biopharma venture, Stelis Biopharma, which will develop and manufacture selected recombinant proteins from the first wave of biosmilars as well as novel biologic therapies targeted against large and under-served treatment markets worldwide.

The Company has 5 manufacturing facilities presence in more than 75 countries in developed and emerging markets. Additional information is available at the Company's website at

About Oncobiologics, Inc.Oncobiologics is a privately held biopharmaceutical company developing a pipeline of biosimilars and next generation biotherapeutics. Formed by a team of leading industry experts from firms such as Eli Lilly, Bristol-Myers Squibb, Amgen, Genentech, Merck and Pfizer, Oncobiologics operates from a state-of-the-art 40,000 sq. ft. fully integrated R&D and Manufacturing facility in Cranbury, NJ. For more information, please visit 

For further information, please contact:

Strides Arcolab Limited

Oncobiologics, Inc.  

Mr. Joe Thomas

Business Development: Chief Corporate Development Officer

Stephen J. McAndrew,
+91 80 6784 0119

Senior Vice President, Business Strategy & Development  

Vikesh Kumar +91 80 6784 0827  

Kannan. N: +91 98450 54745  

  PR ConsultancyMedia:  

Rick GregoryWeber Shandwick

Director of Marketing & CommunicationsKaveri Mandanna: +91 90089 59697                                          


Mahesh Nair:  +91 98803 76648  

SOURCE Oncobiologics, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Molecular eat now signal makes cells devour dying neighbors
2. ITRA Global Report Makes the Case That Bio Tech Companies Should Consider Tucson, Arizona for Relocation or Expansion
3. ExakTime Makes 2013 Inc. 500
4. 5000 List for the Fourth Time
5. NeriumAD Makes Headlines at an Emmy Gifting Suite
6. Personalized Medicine Makes Its Way to Pets With Cancer: Morphogenesis and SEVO-Med Team up for a Canine Cancer Field Study, First of Its Kind, Side-Effect-Free Process to Treat Companion Animals
7. Lawrence Livermore engineering team makes breakthrough in solar energy research
8. Pittsburgh Life Sciences Greenhouse Makes Strategic Adjustment To Put Laser Focus On 2013 Goals
9. The Employment Report for July, 2013: Nation's Economy Makes Substantial, Demonstrable Improvements
10. Accel-KKR Makes Growth Equity Investment in Zinc Ahead, Leading Provider of Marketing Compliance Solutions for the Life Sciences Industry
11. Pittsburgh Life Sciences Greenhouse Makes Significant Reductions Due to Uncertain Funding
Post Your Comments:
(Date:11/27/2015)... Kingdom , Nov. 27, 2015 /PRNewswire/--  Mallinckrodt plc ... company, announced today that it has closed the sale ... business to Guerbet (GBT- NYSE Euronext) in a transaction ... encompassed four manufacturing facilities and a total of approximately ... in the St. Louis area. ...
(Date:11/27/2015)... PA (PRWEB) , ... November 27, 2015 , ... ... Technical Program that includes over 2,000 technical presentations offered in symposia, oral ... chemistry and applied spectroscopy, covers a wide range of applications such as, but ...
(Date:11/27/2015)... India , November 27, 2015 /PRNewswire/ ... --> Growing popularity of companion diagnostics ... in cancer biomarkers market with pharmaceutical companies ... in-demand companion diagnostic tests. ... --> Complete report on global cancer ...
(Date:11/26/2015)... November 26, 2015 ... Accutest Research Laboratories, a leading ... Organization (CRO), has formed a strategic ... - Temple Health for joint work ... (Photo: ) , --> ...
Breaking Biology Technology:
(Date:11/19/2015)... Calif. , Nov. 19, 2015  Based on ... Frost & Sullivan recognizes BIO-key with the 2015 Global ... Each year, Frost & Sullivan presents this award to ... line catering to the needs of the market it ... product line meets and expands on customer base demands, ...
(Date:11/18/2015)... PHILADELPHIA , Nov. 18, 2015  As new ... in children, doctors and other healthcare providers face challenges ... counsel families and patients. In addition, as more children ... into a patient,s adulthood and old age. ... The Children,s Hospital of Philadelphia (CHOP) . ...
(Date:11/17/2015)... Paris from 17 th until ... from 17 th until 19 th November ... has invented the first combined scanner in the world which scans ... Until now two different scanners were required: one for passports ... on the same surface. This innovation is an ideal solution ...
Breaking Biology News(10 mins):